Sun Pharma inks $55.5-mn deal for anti-psoriasis drug

Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis," the company said in a BSE filing.PTI | July 04, 2017, 12:25 IST

"The agreement was entered into by Sun Pharma's wholly- owned subsidiary and Samsung BioLogics...Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis," the company said in a BSE filing.

Sun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential.

It further said: "Filings for this novel investigational biologic has been accepted for review by the US Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017)".

The agreement was signed at Samsung BioLogics' headquarter in Incheon, South Korea.

Shares of Sun Pharma were trading 0.55 per cent lower at Rs 548.45 on BSE.

Subscribe to our Newsletters

Consumption of food contaminated with Salmonella can cause salmonellosis, one of the most common bacterial food-borne illnesses. The most common symptoms of salmonellosis are diarrhea, abdominal cramps, and fever within 12 to 72 hours after eating the contaminated product.

According to the research published in the journal 'Cancer Prevention Research', the most significant reduction in risk occurred in the first 10 years after quitting, with a modest but continued decline in later years.